Skip to main content
. 2018 Jun 18;8:226. doi: 10.3389/fonc.2018.00226

Table 3.

Approved targeted therapies for GI cancer.

GI cancer Drug Target
Gastric cancer Trastuzumab HER2
Ramucirumab VEGFR-2
Pembrolizumab PD-1
Hepatocellular cancer Sorafenib RAF, VEGFR-2, VEGFR-3, PDGFR, c-KIT
Colon cancer Cetuximab, panitumumab EGFR
Bevacizumab VEGF
Regorafenib VEGFR-1, VEGFR-2, VEGFR-3, BRAF, c-KIT, RET, PDGFR
Colon cancer with MSI-H Pembrolizumab PD-1

HER2, human epidermal growth factor receptor 2; VEGFR, vascular endothelial growth factor receptor; PD-1, programmed cell death protein-1; RAF, rapidly accelerated fibrosarcoma; PDGFR, platelet-derived growth factor receptor; c-KIT, SCFR, mast/stem cell growth factor receptor; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; RET, rearranged during transfection; MSI-H, microsatellite instability-high.